Clinical Trial Detail

NCT ID NCT02337491
Title Pembrolizumab +/- Bevacizumab for Recurrent GBM
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma multiforme

gliosarcoma

malignant glioma

Therapies

Pembrolizumab

Bevacizumab + Pembrolizumab

Age Groups: adult

No variant requirements are available.